33 completed, 22 terminated, 13 active not recruiting, 10 recruiting. 92 Phase 1, 37 Phase 2.
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma CY-219 CAR-T - Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-05-01 | 2026-04-20 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 150 | 2025-08-19 | 2026-04-01 |
| Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab, Roflumilast, Rituximab - Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 10 | 2025-06-20 | 2026-09-29 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL R-CMOP Regimen, R-CHOP Regimen - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 112 | 2025-01-10 | 2025-04-03 |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) Zilovertamab vedotin - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 90 | 2024-08-16 | 2026-10-30 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX) - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 108 | 2024-05-30 | 2026-06-10 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 40 | 2023-08-30 | 2026-05-06 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-08-01 | 2026-02-23 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) ABBV-319 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 39 | 2023-04-26 | 2026-08-28 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets ABBV-525 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 78 | 2023-04-04 | 2026-05-04 |
| A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL MT-2111 - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Tanabe Pharma Corporation | 46 | 2023-01-30 | 2026-06-09 |
Showing 20 of 92. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (92) · Lymphoma, Non-Hodgkin (18) · Lymphoma, Follicular (17) · Lymphoma, Mantle-Cell (15) · Lymphoma (12) · Burkitt Lymphoma (10) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Leukemia, Myeloid, Acute (8) · Multiple Myeloma (8) · Lymphoma, B-Cell, Marginal Zone (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Recurrence (6) · Lymphoma, B-Cell (5) · Lymphoma, T-Cell, Peripheral (5) · Neoplasms (5)
Hemic and Lymphatic Diseases (92) · Immune System Diseases (92) · Immunoproliferative Disorders (92) · Lymphatic Diseases (92) · Lymphoproliferative Disorders (92) · Neoplasms by Histologic Type (92) · Lymphoma, B-Cell (87) · Neoplasms (87) · Lymphoma (80) · Lymphoma, Non-Hodgkin (74) · Hematologic Diseases (23) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Disease Attributes (16) · Leukemia (14)
Rituximab (30) · Cyclophosphamide (19) · Prednisone (19) · Vincristine (18) · Doxorubicin (15) · Etoposide (10) · Lenalidomide (9) · deltacortene (7) · ibrutinib (7) · venetoclax (7) · loncastuximab tesirine (6) · polatuzumab vedotin (6) · prednylidene (6) · CT-P10 (5) · Dexamethasone (5)
Novartis Pharmaceuticals (5) · ADC Therapeutics S.A. (4) · Pfizer (4) · AbbVie (3) · Fred Hutchinson Cancer Center (3) · National Cancer Institute (NCI) (3) · BeOne Medicines (2) · City of Hope Medical Center (2) · Genmab (2) · Gilead Sciences (2) · Hoffmann-La Roche (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Jonsson Comprehensive Cancer Center (2) · Massachusetts General Hospital (2) · MedImmune LLC (2)
United States (64) · Spain (19) · France (15) · China (12) · Italy (11) · United Kingdom (11) · South Korea (9) · Germany (8) · Australia (7) · Belgium (7) · Canada (7) · Japan (7) · Israel (5) · Netherlands (5) · Taiwan (5)
Christopher J Melani, M.D. (2) · Jeremy Abramson, MD (2) · Adolfo E Diaz Duque, MD (1) · Ajay Gopal (1) · Alejandro Martin (1) · Alex Herrera (1) · Alexey V Danilov (1) · Andres Forero-Torres, MD (1) · Anthony J Reiman (1)
PMID 34515338, PMID 24352795, PMID 26341814, PMID 27063977, PMID 27063978, PMID 27354476, PMID 28490569, PMID 28903943, PMID 29903707, PMID 30082475, PMID 30301414, PMID 30935953, PMID 30937889, PMID 31395089, PMID 31609651, PMID 32556281, PMID 32705923, PMID 32770353, PMID 32871584, PMID 33785483, PMID 34398557, PMID 34581757, PMID 34634256, PMID 35244520, PMID 36044388, PMID 36398795, PMID 36536403, PMID 37369099, PMID 37485564, PMID 38237077, PMID 38319241, PMID 38683495, PMID 38899693, PMID 39319495, PMID 39792928, PMID 39793445, PMID 40184567, PMID 40641817, PMID 40802906, PMID 40920572, PMID 41536778, PMID 41563911, PMID 41784015, PMID 41796974, PMID 42622258, PMID 42660129, PMID 42832423
2018 (4), 2017 (2), 2019 (2), 2023 (2), P30CA015704 (2), P30CA033572 (2), P30CA060553 (2), 2015 (1), 2016 (1), P01CA044991 (1), P01CA078902 (1), P30CA022453 (1), P50CA107399 (1)